MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations - Santarpia - Translational Lung Cancer Research
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Diagnosis and Discussion -- Case 1068
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Locations of MET exon 14 genomic alterations found in sarcomatoid... | Download Scientific Diagram
Figure 2 from MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. | Semantic Scholar
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Diagnosis and Discussion -- Case 1068
Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small-cell Lung Cancer - Clinical Lung Cancer
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
PLOS ONE: MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population
Schematic representation of MET mutations that lead to exon 14... | Download Scientific Diagram
MET Mutation Associated with Responsiveness to Crizotinib. - Abstract - Europe PMC
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro - Journal of Thoracic Oncology
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Fragment Analysis Is a More Reliable MET Exon 14 Screening Strate
Lung cancer with MET exon 14 skipping mutation | LCTT
![MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/67fdcd54f931874b6e6ffa4ffca44de1124ea7f0/5-Figure1-1.png "MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar")
MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer]. | Semantic Scholar
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values - Journal of Thoracic Oncology
Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients - ScienceDirect
